MONTREAL, CANADA--(Marketwire - April 14, 2008) - ART Advanced Research Technologies Inc. (“ART”) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that it has received a Letter of Intent (LOI) to purchase its Optix® MX2 preclinical optical molecular imaging system, from the Southern California-based CRO firm BioLaurus, Inc. The announcement was made at the annual AACR meeting in San Diego, which ART is attending as an exhibitor.
